Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Status: | Recruiting |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 10 - 17 |
Updated: | 10/2/2013 |
Start Date: | September 2006 |
End Date: | January 2019 |
Contact: | Emergingmed |
Email: | faptrials@emergingmed.com |
Phone: | 1-877-769-4832 |
A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis
To test whether celecoxib can be used to prevent colon polyp formation in children with
familial adenomatous polyposis (FAP).
Inclusion Criteria:
- Age 10-17 years
- Confirmed deleterious FAP genotype based on central genetic testing or personal
history ot >2 colorectal adenomas and a parent with the diagnosis of FAP and either
A, B or C below A: Non-attenuated FAP genotype B: Attenuated FAP genotype and a
personal history of colorectal adenomas and a first degree relative with FAP C: No
genotype identified with a personal history of > 2 adenomas and have a parent with
FAP
- Less than 30 polyps, which need to be removed to render the colon polyp-free before
study drug can be given
Exclusion Criteria:
- Diagnosis of attenuated FAP based on central genetic testing in the absence of a
personal history of >2 colorectal adenomas and a first degree relative (parent or
sibling) with FAP.
- Sensitivity to COX-2 inhibitors
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials